= 26.38, ~50% past-month cannabis use by design) completed an online survey. Multivariable regression assessed sociodemographics, mental health, and adverse childhood events (ACEs) in relation to: (1) past-year psychedelic use; and (2) among those reporting lifetime use: (a) lifetime microdosing and (b) use motives. Lifetime and past-year psychedelic use wer...
Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition in which prenatal stress and long-lasting disruptions of excitatory-inhibitory (E/I) balance have been implicated as key vulnerability factors. Although established pharmacological and behavioral treatments are effective for many individuals, they are not universally ...
While prior research links psychedelic use to improved psychological outcomes, less is known about whether psychedelic exposure relates to engagement with formal mental health care when treatment is recognized as needed. Using publicly available, de-identified pooled data from the National Survey on Drug Use and Health (2008-2019), this study examines whethe...
Importance: Cocaine use disorder is a serious public health problem and no medications have been proven effective for its treatment. Objective: To evaluate psilocybin in the treatment of cocaine use disorder. It was hypothesized that psilocybin, compared with placebo, would yield a higher percentage of cocaine abstinent days, a greater likelihood of complete...
Background: Little research investigates the role of rarely used drugs in criminal offending. Moreover, given research suggesting that psychedelics reduce criminal offending, more research is needed to further document connections between psychedelics and crime. Aim: This study examines the role of rarely used drugs in criminal behavior and extends previous ...
Despite decades of neuroscience research and significant investment in addiction neuroimaging, clinical outcomes for individuals with substance use and behavioural addictions remain poor. Only 1.8% of people with substance use disorders receive effective treatment, highlighting a major disconnect between mechanistic understanding and clinical utility. This p...
Tobacco use remains a leading cause of preventable morbidity and mortality worldwide, and current smoking cessation treatments are limited by low long-term efficacy. An interplay between positive and negative reinforcement drives high relapse rates. Psychedelic compounds, particularly psilocybin, have shown promising clinical outcomes for smoking cessation, ...
Psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) have remerged as agents of psychiatric and cultural relevance. However, public discourse has outpaced empirical understanding of their effects. Although hallucinogens have demonstrated a potential to treat certain mental disorders, their effect on aggression and violen...
In 1970, Congress passed the Controlled Substances Act and swiftly placed psilocybin (the active chemical in “magic mushrooms”) under Schedule I-the strictest level of regulation withheld for substances with “no currently accepted medical use.” While the United States has maintained this rigid framework, Jamaica has taken the opposite approach. Psilocybin wa...
OBJECTIVE: Despite growing research on the potential mental health benefits of psychedelics, there has been limited study of these drugs in populations with obsessive-compulsive disorder (OCD) and with Hispanic and Latin American (H/L) ancestry. METHODS: Demographic and clinical assessments were conducted as part of the Latin American Trans-ancestry Initiati...
There is renewed interest in the therapeutic properties of hallucinogens in the treatment of psychiatric disorders including alcohol use disorder (AUD). Interestingly, however, there is little data regarding the comorbid use of hallucinogens and alcohol among persons with AUD. The paucity of such data constrains both scientific interpretation and treatment d...
BackgroundPsychedelic-assisted therapy refers to a group of therapeutic practices involving psychedelics taken under therapeutic supervision from physicians, psychologists, and others. It has been hypothesised that psychedelic-assisted therapy may reduce symptoms of anxiety, depression, and existential distress in patients facing life-threatening diseases (e...
As a proposed mediator between stigma-related stressors and negative mental health outcomes, HIV-related shame has been predictive of increased rates of substance use and difficulties adhering to antiretroviral treatment among people with HIV. These downstream manifestations have ultimately impeded progress toward national goals to End the HIV Epidemic, in p...
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from ...
Introduction: Treatment-outcome expectancies are an individual’s beliefs about how a medical or psychological intervention will affect them and others. These response expectancies represent serious potential confounds to clinical trials of psychedelic-assisted therapies for a variety of conditions because of difficulties associated with blinding psychedelic ...
BACKGROUND AND AIMS: Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD- and psilocybin-related death in Australia, 2000-23; and (2) determine the toxicological profile and major...
